Eckert & Ziegler BEBIG: First Quarter 2013 Interim Statement
(Thomson Reuters ONE) -
Regulated information
First Quarter 2013 Interim Statement
Seneffe - Belgium, May 3, 2013, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters:
EZBG.BR; Bloomberg: EZBG:BB) has announced today its Interim Statement for the
first quarter 2013.
The Interim Statement report including the milestones of the 1st quarter 2013
and a selection of consolidated key figures for the 3 months ending March
31, 2013 can be downloaded at:
www.bebig.eu > Investor Relations > Financial Reports
Sales for the 1st quarter 2013 reached 5.5 million EUR, compared to 7.2 million
EUR in 1st quarter 2012, showing a decrease of 23.8%. The main components were
income generated by the sales of permanent brachytherapy I-125 (Iodine-125)
radiotherapeutic implants as well as income from temporary brachytherapy
equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium-192)
sources (also called "afterloaders").
Earnings before interest and taxes (EBIT) have reached 1.0 million EUR in the
1st quarter 2013, versus 0.5 million EUR in the 1st quarter 2012, showing an
increase of 79.6%.
Net profit reached 0.6 million EUR in the 1st quarter 2013, compared to the net
profit of 0.1 million EUR in the 1st quarter 2012.
Total equity of the group stood at 43.6 million EUR on March 31, 2013, versus
42.9 million EUR in December 31, 2012.
Cash amounted to 2.3 million EUR at the end of March 2013, versus 3.3 million
EUR in December 2012. The equity to assets ratio stood at 72.8% end of March
2013.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device
sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and
is headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India and in Brazil. Eckert &
Ziegler BEBIG has also established a worldwide network of distributors and
agents to support its product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the
Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG: BB).
Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel: +32 (0) 64 520 808
E-mail: ir(at)bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1698839]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Cadan Announces USD$5 Million Loan FacilityDatum: 03.05.2013 - 07:47 Uhr
Sprache: Deutsch
News-ID 255847
Anzahl Zeichen: 3416
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 176 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG: First Quarter 2013 Interim Statement"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
